On the End of a Nightmare (COVID-19). The Role of the Immune System
DOI:
https://doi.org/10.14738/jbemi.96.13714Keywords:
COVID-19, subvariants, immune system, vaccines, VITTAbstract
After the Chinese epidemic of Wuhan and the global pandemic that followed, the spread of the coronavirus CoV-SARS-2 has finally come to an end. Already declared the end in the United Kingdom on 19 July 2021, which had primarily started vaccinations on 8 December 2020, aimed in particular at "over" 80 and frail subjects, the whole world has aligned, in particular also taking into account the therapies oral and monoclonal antibodies with a virus that while maintaining its contagiousness has reduced in its virulence. The African continent has stood out for its endemicity linked to zoonoses of the beta coronavirus family. Finally, particular importance is given to the natural infection from COVID-19 and to the immune response with the vaccination exemption due to the risk of thrombi due to genetic mutation and antibody overload.
References
Tarro G. Environment and Virus Interactions: Towards a Systematic Therapy of SARS-CoV-2. British Journal of Healthcare and Medical Research, vol. 9, n. 4. 25 August, 2022.
Zhang L, Alexia R, Khalil A et al. Sars Cov-2 RNA reverse- transcribed and integrated into the human genome. Bio RXiv 13;2020.12.12.422516. December 2020.
Dupont SC and Galea S. Science, Competing Values, and Trade-offs in Public Health – The Example of COVID-19 and Masking. New Engl J Med 387:10. September 8, 2022.
Qu P, Faraone JN and Liu SL. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants. New Engl J Med 387;14. October 6, 2022. 196 Tarro, G. (2022). On the End of a Nightmare (COVID-19). The Role of the Immune System. British Journal of Healthcare and Medical Research, 9(6). 194-197.
Collie S and Nayager J. Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa. New Engl J Med 387;14. Ocotber 6, 2022.
Malato J, Gomes MC and Graca L. Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants. New Engl J Med 387;10. September 8, 2022.
Thompson MA, Henderson JP, Shah PK et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA on Coll 17;7(8):1167-1175. June 2021.
Focosi D, Franchini M, Pirofski LA et al. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev, 21;35(3):e0020021. March 9, 2022.
Sullivan DJ, Gebo KA, Shoham S et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N Engl J Med 2022; 386:1700-1711, May 5, 2022.
Li M, Beck EJ, Laeyendecker O et al. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Adv 6:3678-83; June 2022.
Havervall S, Marking U and Thalin C. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. New Engl J Med 387;14. October 6, 2022.
Chalkias S, Harper C, Vrbicky K et al. A Bivalent Omicron-Containing Booster Vaccine against COVID-19. New Engl J Med 387;14. October 6, 2022.
Basso C. Myocarditis. New engl J Med 387;16. October 20,2022.
Herrera-Comoglio R and Lane S. Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine. N Engl J Med 2022; 387:1431-1432, October 13, 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Giulio Tarro
This work is licensed under a Creative Commons Attribution 4.0 International License.
